Breaking News

Aptar CSP’s Activ-Blister Solutions Available for Manufacturing in Europe

Expanded production of Activ-Blister technology globally is the result of a collaboration between Aptar CSP, Uhlmann and Ivers-Lee.

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptar CSP Technologies, part of AptarGroup, Inc. and a provider of active material science solutions for product protection, extend shelf life and improve patient experience, announced its new manufacturing site is now able to produce its Activ-Blister Solutions for oral slide dose drugs in Europe. The move is part of a key strategic effort to expand production of Activ-Blister technology globally and is the result of a 3-way collaboration between Aptar CSP, Uhlmann, a pharmaceutical packaging equipment manufacturer, and Ivers-Lee, a local contract manufacturing organization.

This collaboration consists of a fully automated Uhlmann blister machine validated to package oral solid dose drug products with Activ-Blister Solutions heat-staked to the foil at a rate of up to 250 blisters per minute. The equipment is designed to integrate Activ-Blister technology into the blister cavity with precision placement. The equipment has been fully-validated and is in place at Ivers-Lee, a CMO capable of manufacturing Activ-Blister™ solutions from R&D to commercialization. A CMO in EMEA will support regional customers and help ensure speed-to-market.

“Expanding global manufacturing sites for Activ-Blister technology reflects our commitment to delivering global access to innovative active material science solutions for patients and consumers,” said Badre Hammond, VP Commercial Operations and GM APAC, Aptar CSP Technologies. “With manufacturing capabilities now available in in both the US and EMEA, we will turn our attention to bringing production of this technology to the Asia market.”

Activ-Blister Solutions integrates Aptar CSP’s 3-Phase Activ-Polymer platform technology into individual blister cavities to provide precision microclimate protection for sensitive drug products. This technology can be customized specifically for the drug developer’s formulation to provide a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters